Tilray Brands (NASDAQ:TLRY – Get Free Report) and Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.
Profitability
This table compares Tilray Brands and Tarsus Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tilray Brands | -13.11% | -7.76% | -5.59% |
| Tarsus Pharmaceuticals | -7.67% | -13.53% | -8.12% |
Analyst Ratings
This is a summary of recent ratings and recommmendations for Tilray Brands and Tarsus Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tilray Brands | 1 | 3 | 2 | 1 | 2.43 |
| Tarsus Pharmaceuticals | 1 | 2 | 5 | 2 | 2.80 |
Earnings and Valuation
This table compares Tilray Brands and Tarsus Pharmaceuticals”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tilray Brands | $915.45 million | 0.63 | -$121.40 million | ($1.08) | -3.90 |
| Tarsus Pharmaceuticals | $451.36 million | 8.05 | -$66.42 million | ($1.09) | -75.94 |
Tarsus Pharmaceuticals has lower revenue, but higher earnings than Tilray Brands. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
9.3% of Tilray Brands shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 0.8% of Tilray Brands shares are held by company insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Risk and Volatility
Tilray Brands has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500.
Summary
Tarsus Pharmaceuticals beats Tilray Brands on 8 of the 15 factors compared between the two stocks.
About Tilray Brands
Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Receive News & Ratings for Tilray Brands Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray Brands and related companies with MarketBeat.com's FREE daily email newsletter.
